{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:13:51Z","timestamp":1791274431354,"version":"4.1.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"2","content-domain":{"domain":["europeanneuropsychopharmacology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.euroneuro.2013.10.002","type":"journal-article","created":{"date-parts":[[2013,10,17]],"date-time":"2013-10-17T19:30:48Z","timestamp":1382038248000},"page":"242-250","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"title":["In vivo type 1 cannabinoid receptor availability in Alzheimer's disease"],"prefix":"10.1016","volume":"24","author":[{"given":"Rawaha","family":"Ahmad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolien","family":"Goffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Van den Stock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois-Laurent","family":"De Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evy","family":"Cleeren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Bormans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos","family":"Tournoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Persoons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen","family":"Van Laere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Vandenbulcke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2013.10.002_bib1","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1001\/archneur.65.11.1509","article-title":"Frequent amyloid deposition without significant cognitive impairment among the elderly","volume":"65","author":"Aizenstein","year":"2008","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.euroneuro.2013.10.002_bib2","first-page":"555","article-title":"[Geriatric Depression Scale (GDS). Validity and reliability of different versions of the scale\u2014review]","volume":"45","author":"Albinski","year":"2011","journal-title":"Psychiatr. Pol."},{"key":"10.1016\/j.euroneuro.2013.10.002_bib3","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3233\/JAD-2012-111862","article-title":"CB1 agonist ACEA protects neurons and reduces the cognitive impairment of AbetaPP\/PS1 mice","volume":"30","author":"Aso","year":"2012","journal-title":"J. Alzheimer's Dis.: JAD"},{"key":"10.1016\/j.euroneuro.2013.10.002_bib4","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1017\/S1355617709990956","article-title":"Learning, retrieval, and recognition are compromised in aMCI and mild AD: are distinct episodic memory processes mediated by the same anatomical structures?","volume":"16","author":"Balthazar","year":"2010","journal-title":"J. Int. Neuropsychol. Soc."},{"key":"10.1016\/j.euroneuro.2013.10.002_bib5","doi-asserted-by":"crossref","first-page":"11136","DOI":"10.1523\/JNEUROSCI.23-35-11136.2003","article-title":"Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains","volume":"23","author":"Benito","year":"2003","journal-title":"J. Neurosci."},{"key":"10.1016\/j.euroneuro.2013.10.002_bib6","doi-asserted-by":"crossref","first-page":"9800","DOI":"10.1073\/pnas.0703472104","article-title":"[18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor","volume":"104","author":"Burns","year":"2007","journal-title":"Proc. Nat. Acad. Sci. U.S.A"},{"key":"10.1016\/j.euroneuro.2013.10.002_bib7","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1126\/science.8346443","article-title":"Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families","volume":"261","author":"Corder","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.euroneuro.2013.10.002_bib8","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1212\/WNL.48.5_Suppl_6.10S","article-title":"The neuropsychiatric inventory: assessing psychopathology in dementia patients","volume":"48","author":"Cummings","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.euroneuro.2013.10.002_bib9","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/S0028-3908(02)00060-6","article-title":"Functions of cannabinoid receptors in the hippocampus","volume":"42","author":"Davies","year":"2002","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.euroneuro.2013.10.002_bib10","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S1474-4422(07)70178-3","article-title":"Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria","volume":"6","author":"Dubois","year":"2007","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.euroneuro.2013.10.002_bib11","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.neuint.2011.11.004","article-title":"[(125)I]SD-7015 reveals fine modalities of CB(1) cannabinoid receptor density in the prefrontal cortex during progression of Alzheimer's disease","volume":"60","author":"Farkas","year":"2012","journal-title":"Neurochem. Int."},{"issue":"Suppl 2","key":"10.1016\/j.euroneuro.2013.10.002_bib12","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1097\/00002093-199700112-00005","article-title":"An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's disease cooperative study","volume":"11","author":"Galasko","year":"1997","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"10.1016\/j.euroneuro.2013.10.002_bib13","doi-asserted-by":"crossref","first-page":"432","DOI":"10.2174\/187152709789824642","article-title":"Cannabinoids and Parkinson's disease","volume":"8","author":"Garcia-Arencibia","year":"2009","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.euroneuro.2013.10.002_bib14","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0306-4522(00)00008-7","article-title":"The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease","volume":"97","author":"Glass","year":"2000","journal-title":"Neuroscience"},{"key":"10.1016\/j.euroneuro.2013.10.002_bib15","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/0306-4522(93)90352-G","article-title":"Loss of cannabinoid receptors in the substantia nigra in Huntington's disease","volume":"56","author":"Glass","year":"1993","journal-title":"Neuroscience"},{"key":"10.1016\/j.euroneuro.2013.10.002_bib16","first-page":"1689","article-title":"11C-JHU75528: a radiotracer for PET imaging of CB1 cannabinoid receptors","volume":"47","author":"Horti","year":"2006","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.euroneuro.2013.10.002_bib17","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1080\/13854046.2010.521982","article-title":"The diagnostic accuracy of an incidental memory modification of the Boston Naming Test (memo-BNT) in differentiating between normal aging and mild Alzheimer's disease","volume":"24","author":"Karrasch","year":"2010","journal-title":"Clin. Neuropsychol."},{"key":"10.1016\/j.euroneuro.2013.10.002_bib18","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/ana.20009","article-title":"Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B","volume":"55","author":"Klunk","year":"2004","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.euroneuro.2013.10.002_bib19","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1046\/j.0953-816x.2001.01812.x","article-title":"Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets","volume":"14","author":"Lastres-Becker","year":"2001","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.euroneuro.2013.10.002_bib20","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1126\/science.283.5400.401","article-title":"Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice","volume":"283","author":"Ledent","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.euroneuro.2013.10.002_bib21","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.neuint.2010.10.010","article-title":"Intact cannabinoid CB1 receptors in the Alzheimer's disease cortex","volume":"57","author":"Lee","year":"2010","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.euroneuro.2013.10.002_bib22","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/ana.23797","article-title":"In vivo assessment of amyloid-beta deposition in nondemented very elderly subjects","volume":"73","author":"Mathis","year":"2013","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.euroneuro.2013.10.002_bib23","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ejphar.2003.08.026","article-title":"Amnesia induced by beta-amyloid fragments is counteracted by cannabinoid CB1 receptor blockade","volume":"477","author":"Mazzola","year":"2003","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2013.10.002_bib24","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3389\/fphar.2012.00110","article-title":"Endocannabinoid modulation of dopaminergic motor circuits","volume":"3","author":"Morera-Herreras","year":"2012","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.euroneuro.2013.10.002_bib25","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1212\/WNL.43.11.2412-a","article-title":"The Clinical Dementia Rating (CDR): current version and scoring rules","volume":"43","author":"Morris","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.euroneuro.2013.10.002_bib26","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1093\/brain\/awm133","article-title":"Abeta amyloid deposition in the language system and how the brain responds","volume":"130","author":"Nelissen","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.euroneuro.2013.10.002_bib27","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1001\/archneur.65.7.963","article-title":"Detecting dementia with the mini-mental state examination in highly educated individuals","volume":"65","author":"O\u2019Bryant","year":"2008","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.euroneuro.2013.10.002_bib28","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.2174\/138161208785740108","article-title":"The endocannabinoid system in Huntington's disease","volume":"14","author":"Pazos","year":"2008","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.euroneuro.2013.10.002_bib29","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1124\/pr.57.2.2","article-title":"Multiple signaling states of G-protein-coupled receptors","volume":"57","author":"Perez","year":"2005","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.euroneuro.2013.10.002_bib30","first-page":"192","article-title":"Integrated software for the analysis of brain PET\/SPECT studies with partial-volume-effect correction","volume":"45","author":"Quarantelli","year":"2004","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.euroneuro.2013.10.002_bib31","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1523\/JNEUROSCI.4540-04.2005","article-title":"Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation","volume":"25","author":"Ramirez","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.euroneuro.2013.10.002_bib32","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1016\/S0014-2999(99)00496-3","article-title":"Enhancement of memory in cannabinoid CB1 receptor knock-out mice","volume":"379","author":"Reibaud","year":"1999","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2013.10.002_bib33","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1073\/pnas.2635903100","article-title":"Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia","volume":"101","author":"Reiman","year":"2004","journal-title":"Proc. Nat. Acad. Sci. U.S.A"},{"key":"10.1016\/j.euroneuro.2013.10.002_bib34","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.pneurobio.2012.06.010","article-title":"The serotonergic system in ageing and Alzheimer's disease","volume":"99","author":"Rodriguez","year":"2012","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.euroneuro.2013.10.002_bib35","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1007\/s00259-009-1340-5","article-title":"Kinetic analysis of the cannabinoid-1 receptor PET tracer [(18)F]MK-9470 in human brain","volume":"37","author":"Sanabria-Bohorquez","year":"2010","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.euroneuro.2013.10.002_bib36","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s11682-012-9166-3","article-title":"The Alzheimer's Disease Assessment Scale-Cognitive-Plus (ADAS-Cog-Plus): an expansion of the ADAS-Cog to improve responsiveness in MCI","volume":"6","author":"Skinner","year":"2012","journal-title":"Brain Imaging Behav."},{"key":"10.1016\/j.euroneuro.2013.10.002_bib37","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.neurobiolaging.2012.06.005","article-title":"CB2 receptor and amyloid pathology in frontal cortex of Alzheimer's disease patients","volume":"34","author":"Solas","year":"2013","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.euroneuro.2013.10.002_bib38","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/BF02246352","article-title":"Improvement of memory in rodents by the selective CB1 cannabinoid receptor antagonist, SR 141716","volume":"126","author":"Terranova","year":"1996","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.euroneuro.2013.10.002_bib39","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.neuroimage.2008.03.004","article-title":"Positron emission tomography imaging using an inverse agonist radioligand to assess cannabinoid CB1 receptors in rodents","volume":"41","author":"Terry","year":"2008","journal-title":"Neuroimage"},{"key":"10.1016\/j.euroneuro.2013.10.002_bib40","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1017\/S1355617705050344","article-title":"Rey's verbal learning test: normative data for 1855 healthy participants aged 24-81 years and the influence of age, sex, education, and mode of presentation","volume":"11","author":"Van der Elst","year":"2005","journal-title":"J. Int. Neuropsychol. Soc.: JINS"},{"key":"10.1016\/j.euroneuro.2013.10.002_bib41","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.2967\/jnumed.110.077156","article-title":"Widespread decrease of type 1 cannabinoid receptor availability in huntington disease in vivo","volume":"51","author":"Van Laere","year":"2010","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.euroneuro.2013.10.002_bib43","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.neuroimage.2007.10.053","article-title":"Gender-dependent increases with healthy aging of the human cerebral cannabinoid-type 1 receptor binding using [(18)F]MK-9470 PET","volume":"39","author":"Van Laere","year":"2008","journal-title":"Neuroimage"},{"key":"10.1016\/j.euroneuro.2013.10.002_bib44","first-page":"740","article-title":"Metabolic imaging of anterior capsular stimulation in refractory obsessive-compulsive disorder: a key role for the subgenual anterior cingulate and ventral striatum","volume":"47","author":"Van Laere","year":"2006","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.euroneuro.2013.10.002_bib45","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1080\/13554790802570480","article-title":"Use of the Visual Object and Space Perception (VOSP) test battery in two cases of posterior cortical atrophy","volume":"15","author":"Videaud","year":"2008","journal-title":"Neurocase"},{"key":"10.1016\/j.euroneuro.2013.10.002_bib46","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/ana.22248","article-title":"Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease","volume":"69","author":"Villemagne","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.euroneuro.2013.10.002_bib47","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.brainresbull.2010.01.009","article-title":"Loss of cannabinoid CB1 receptor expression in the 6-hydroxydopamine-induced nigrostriatal terminal lesion model of Parkinson's disease in the rat","volume":"81","author":"Walsh","year":"2010","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.euroneuro.2013.10.002_bib48","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1007\/s00213-006-0343-1","article-title":"Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia","volume":"185","author":"Walther","year":"2006","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.euroneuro.2013.10.002_bib49","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/0306-4522(94)90511-8","article-title":"Cannabinoid receptor binding and messenger RNA expression in human brain: an in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer's brains","volume":"63","author":"Westlake","year":"1994","journal-title":"Neuroscience"}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X13002940?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X13002940?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,30]],"date-time":"2019-07-30T23:26:02Z","timestamp":1564529162000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X13002940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S0924977X13002940"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2013.10.002","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vivo type 1 cannabinoid receptor availability in Alzheimer's disease","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2013.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}